{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:40:57Z","timestamp":1784979657916,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejps.2022.106322","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T12:51:14Z","timestamp":1667479874000},"page":"106322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity"],"prefix":"10.1016","volume":"180","author":[{"given":"Habib","family":"Yaribeygi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-3917","authenticated-orcid":false,"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejps.2022.106322_bib0001","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2337\/dc14-1432","article-title":"Trends in diabetes incidence: the Framingham Heart Study","volume":"38","author":"Abraham","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejps.2022.106322_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijcard.2018.09.089","article-title":"Epicardial adipose tissue and cardiovascular diseases","volume":"278","author":"Ansaldo","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"Supplement 1","key":"10.1016\/j.ejps.2022.106322_bib0017","first-page":"S81","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"Supplement 1","key":"10.1016\/j.ejps.2022.106322_bib0014","first-page":"S11","article-title":"2. Classification and diagnosis of diabetes","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0516-8","article-title":"Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study","volume":"16","author":"Bouchi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.ejps.2022.106322_bib0034","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/oby.2008.622","article-title":"Response to\" Epicardial and pericardial fat: close, but very different","volume":"17","author":"Carr","year":"2009","journal-title":"Obesity"},{"issue":"7","key":"10.1016\/j.ejps.2022.106322_bib0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0019","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin. Diab."},{"issue":"6","key":"10.1016\/j.ejps.2022.106322_bib0060","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024593","article-title":"Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus: a systematic review and network meta-analysis","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.ejps.2022.106322_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0048","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability","volume":"114","author":"D\u00edaz-Rodr\u00edguez","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.ejps.2022.106322_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2014.10.2819","article-title":"Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes","volume":"126","author":"Davidson","year":"2014","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejps.2022.106322_bib0015","series-title":"Classification of Diabetes. Diabetes","first-page":"12","author":"de Faria Maraschin","year":"2013"},{"issue":"4","key":"10.1016\/j.ejps.2022.106322_bib0039","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cardiores.2007.05.025","article-title":"Adiponectin is a novel humoral vasodilator","volume":"75","author":"F\u00e9s\u00fcs","year":"2007","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0025","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ejps.2022.106322_bib0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s13300-017-0279-y","article-title":"Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study","volume":"8","author":"Fukuda","year":"2017","journal-title":"Diab. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.ejps.2022.106322_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-019-1107-y","article-title":"Epidemiology of diabetes mellitus and cardiovascular disease","volume":"21","author":"Glovaci","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"issue":"6","key":"10.1016\/j.ejps.2022.106322_bib0023","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-021-01228-3","article-title":"A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study","volume":"20","author":"Hiruma","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"07","key":"10.1016\/j.ejps.2022.106322_bib0044","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-2008-1062724","article-title":"The double role of epicardial adipose tissue as pro-and anti-inflammatory organ","volume":"40","author":"Iacobellis","year":"2008","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ejps.2022.106322_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nut.2018.07.002","article-title":"Epicardial adipose tissue feeding and overfeeding the heart","volume":"59","author":"Iacobellis","year":"2019","journal-title":"Nutrition"},{"issue":"6","key":"10.1016\/j.ejps.2022.106322_bib0047","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/oby.22798","article-title":"Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity","volume":"28","author":"Iacobellis","year":"2020","journal-title":"Obesity"},{"issue":"08","key":"10.1016\/j.ejps.2022.106322_bib0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0043-109563","article-title":"Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes","volume":"49","author":"Iacobellis","year":"2017","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12020-013-0099-4","article-title":"Epicardial adipose tissue in endocrine and metabolic diseases","volume":"46","author":"Iacobellis","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ejps.2022.106322_bib0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fragi.2021.666260","article-title":"Aging effects on epicardial adipose tissue","volume":"2","author":"Iacobellis","year":"2021","journal-title":"Front. Aging"},{"key":"10.1016\/j.ejps.2022.106322_bib0059","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijcard.2021.01.063","article-title":"Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: association with a slight increase in high-density lipoprotein cholesterol","volume":"331","author":"Jojima","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0022","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0056","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/biom12010143","article-title":"Antioxidant roles of sglt2 inhibitors in the kidney","volume":"12","author":"Llorens-Cebri\u00e0","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0040","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/cvr\/cvn034","article-title":"Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells","volume":"78","author":"Mahadev","year":"2008","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0038","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0305-0491(89)90337-4","article-title":"Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties","volume":"94","author":"Marchington","year":"1989","journal-title":"Comp. Biochem. Physiol. B"},{"issue":"8","key":"10.1016\/j.ejps.2022.106322_bib0013","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/cells10082150","article-title":"Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis","volume":"10","author":"Masson","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-34305-x","article-title":"A reduced M1-like\/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition","volume":"8","author":"Miyachi","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ejps.2022.106322_bib0016","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/ds15-0047","article-title":"Recognizing and appropriately treating latent autoimmune diabetes in adults","volume":"29","author":"O'Neal","year":"2016","journal-title":"Second. Diabetes Spectrum Diabetic Syndr."},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0004","doi-asserted-by":"crossref","first-page":"H129","DOI":"10.1152\/ajpheart.00565.2021","article-title":"Epicardial adipose tissue as a mediator of cardiac arrhythmias","volume":"322","author":"Patel","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejps.2022.106322_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!","volume":"101","author":"Ranjbar","year":"2019","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0031","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12020-016-0943-4","article-title":"SGLT2 inhibitors in the management of type 2 diabetes","volume":"53","author":"Reddy","year":"2016","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.ejps.2022.106322_bib0045","first-page":"578","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"Heart Fail."},{"issue":"12","key":"10.1016\/j.ejps.2022.106322_bib0037","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1440-1681.2011.05601.x","article-title":"Human epicardial fat: what is new and what is missing?","volume":"38","author":"Sacks","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"9","key":"10.1016\/j.ejps.2022.106322_bib0042","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1210\/jc.2009-0571","article-title":"Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat","volume":"94","author":"Sacks","year":"2009","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejps.2022.106322_bib0011","first-page":"48009","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume and P-wave indices: an ad-hoc analysis of the previous randomized clinical trial","author":"Sato","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"issue":"suppl_1","key":"10.1016\/j.ejps.2022.106322_bib0052","first-page":"A14832","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on epicardial and visceral fat in patients with type 2 diabetes and metabolic syndrome: a randomized controlled trial","volume":"136","author":"Shiina","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0054","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.ejps.2022.106322_bib0041","doi-asserted-by":"crossref","first-page":"H1655","DOI":"10.1152\/ajpheart.01072.2006","article-title":"Adiponectin and cardiovascular disease: state of the art?","volume":"292","author":"Szmitko","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.ejps.2022.106322_bib0032","first-page":"416","article-title":"Epicardial adipose tissue: far more than a fat depot","volume":"4","author":"Talman","year":"2014","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"10.1016\/j.ejps.2022.106322_bib0009","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"issue":"11","key":"10.1016\/j.ejps.2022.106322_bib0036","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ejhf.1283","article-title":"Epicardial fat in heart failure patients with mid-range and preserved ejection fraction","volume":"20","author":"van Woerden","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejps.2022.106322_bib61","doi-asserted-by":"crossref","unstructured":"Wierzba, W., Karnafel, W., \u015aliwczy\u0144ski, A., Pinkas, J., Gujski, M., 2018. Diabetes mellitus and congestive heart failure: the prevalence of congestive heart failure in patients with and without diabetes in Poland. Arch. Med. Sci. 6;17(3):646-651. 10.5114\/aoms.2018.74261. PMID: 34025834.","DOI":"10.5114\/aoms.2018.74261"},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0024","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diab. Obes. Metabol."},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol. Metab. Syndr."},{"issue":"4","key":"10.1016\/j.ejps.2022.106322_bib0006","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.ejps.2022.106322_bib0008","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.dsx.2019.03.031","article-title":"Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes","volume":"13","author":"Yaribeygi","year":"2019","journal-title":"Diab. Metab. Syndr."},{"issue":"1","key":"10.1016\/j.ejps.2022.106322_bib0018","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejps.2022.106322_bib0027","first-page":"152","article-title":"Neuromodulatory effects of anti-diabetes medications: a mechanistic review","author":"Yaribeygi","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.ejps.2022.106322_bib0028","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1871530319666191014110414","article-title":"A review on the effects of new anti-diabetic drugs on platelet function","volume":"20","author":"Yaribeygi","year":"2020","journal-title":"Endocr. Metab. Immune Disord. Targets"},{"key":"10.1016\/j.ejps.2022.106322_bib0030","first-page":"240","article-title":"Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review","author":"Yaribeygi","year":"2020","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.ejps.2022.106322_bib0029","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1002\/jcp.30851","article-title":"Sodium-glucose co-transporter 2 inhibitors and hematopoiesis","volume":"237","author":"Yaribeygi","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejps.2022.106322_bib0057","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"49","key":"10.1016\/j.ejps.2022.106322_bib0053","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018245","article-title":"Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis","volume":"98","author":"Zou","year":"2019","journal-title":"Medicine"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872200207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872200207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:07:12Z","timestamp":1760530032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872200207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":61,"alternative-id":["S092809872200207X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106322","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106322"}}